Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer
The gene profile of primary tumors, as well as the identification of circulating tumor cells (CTCs), can provide important prognostic and predictive information. In this study, our objective was to perform tumor gene profiling (TGP) in combination with CTC characterization in women with nonmetastati...
Gespeichert in:
| Veröffentlicht in: | Tumor biology 2015-09, Vol.36 (10), p.8075-8083 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8083 |
|---|---|
| container_issue | 10 |
| container_start_page | 8075 |
| container_title | Tumor biology |
| container_volume | 36 |
| creator | Kuniyoshi, Renata K. de Sousa Gehrke, Flávia Alves, Beatriz C. A. Vilas-Bôas, Viviane Coló, Anna E. Sousa, Naiara Nunes, João Fonseca, Fernando L. A. Del Giglio, Auro |
| description | The gene profile of primary tumors, as well as the identification of circulating tumor cells (CTCs), can provide important prognostic and predictive information. In this study, our objective was to perform tumor gene profiling (TGP) in combination with CTC characterization in women with nonmetastatic breast cancer. Biological samples (from peripheral blood and tumors) from 167 patients diagnosed with stage I, II, and III mammary carcinoma, who were also referred for adjuvant/neoadjuvant chemotherapy, were assessed for the following parameters: (a) the presence of CTCs identified by the expression of CK-19 and c-erbB-2 in the peripheral blood mononuclear cell (PBMC) fraction by quantitative reverse transcription PCR (RT-PCR) and (b) the TGP, which was determined by analyzing the expression of 21 genes in paraffin-embedded tissue samples by quantitative multiplex RT-PCR with the Plexor® system. We observed a statistically significant correlation between the progression-free interval (PFI) and the clinical stage (
p
= 0.000701), the TGP score (
p
= 0.006538), and the presence of hormone receptors in the tumor (
p
= 0.0432). We observed no correlation between the PFI and the presence or absence of CK-19 or HER2 expression in the PBMC fraction prior to the start of treatment or in the two following readouts. Multivariate analysis revealed that only the TGP score significantly correlated with the PFI (
p
= 0.029247). The TGP is an important prognostic variable for patients with locoregional breast cancer. The presence of CTCs adds no prognostic value to the information already provided by the TGP. |
| doi_str_mv | 10.1007/s13277-015-3529-5 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1768568295</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3836286231</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-66763e07a891cb01bfd9b1c879b026605eab0b124fd5fcd78826d7e46fd374913</originalsourceid><addsrcrecordid>eNqNkUFvFSEUhYnR2Fr9AW4MiRs3oxdmgGFpGq1NmrjRNQHmzpM6D16BifHfy2SqMSYmXQG53zn3Xg4hLxm8ZQDqXWE9V6oDJrpecN2JR-ScDbzvoB_hcbsDg27gY39GnpVyCw3UWj4lZ1xoJQUM5-TuCiPSU05zWEI8UBsn6kP262Lr9q7rMWXqcVkKtYW6kI42f8dMa9pUh5hKDZ6mmZ6aAGMt9Eeo3-iSfMp4CCnahbqMtlTqbfSYn5Mns10Kvrg_L8jXjx--XH7qbj5fXV--v-n8oETtpFSyR1B21Mw7YG6etGN-VNoBlxIEWgeO8WGexOwnNY5cTgoHOU-9GjTrL8ib3beNebdiqeYYyraIjZjWYpiSo5Aj1-IBKOeaC6l1Q1__g96mNbcldwq0ZmJoFNspn1MpGWdzyqF93E_DwGzRmT060xIxW3RmG-LVvfPqjjj9UfzOqgF8B0orxQPmv1r_1_UXm-ykVQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1722099154</pqid></control><display><type>article</type><title>Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Kuniyoshi, Renata K. ; de Sousa Gehrke, Flávia ; Alves, Beatriz C. A. ; Vilas-Bôas, Viviane ; Coló, Anna E. ; Sousa, Naiara ; Nunes, João ; Fonseca, Fernando L. A. ; Del Giglio, Auro</creator><creatorcontrib>Kuniyoshi, Renata K. ; de Sousa Gehrke, Flávia ; Alves, Beatriz C. A. ; Vilas-Bôas, Viviane ; Coló, Anna E. ; Sousa, Naiara ; Nunes, João ; Fonseca, Fernando L. A. ; Del Giglio, Auro</creatorcontrib><description>The gene profile of primary tumors, as well as the identification of circulating tumor cells (CTCs), can provide important prognostic and predictive information. In this study, our objective was to perform tumor gene profiling (TGP) in combination with CTC characterization in women with nonmetastatic breast cancer. Biological samples (from peripheral blood and tumors) from 167 patients diagnosed with stage I, II, and III mammary carcinoma, who were also referred for adjuvant/neoadjuvant chemotherapy, were assessed for the following parameters: (a) the presence of CTCs identified by the expression of CK-19 and c-erbB-2 in the peripheral blood mononuclear cell (PBMC) fraction by quantitative reverse transcription PCR (RT-PCR) and (b) the TGP, which was determined by analyzing the expression of 21 genes in paraffin-embedded tissue samples by quantitative multiplex RT-PCR with the Plexor® system. We observed a statistically significant correlation between the progression-free interval (PFI) and the clinical stage (
p
= 0.000701), the TGP score (
p
= 0.006538), and the presence of hormone receptors in the tumor (
p
= 0.0432). We observed no correlation between the PFI and the presence or absence of CK-19 or HER2 expression in the PBMC fraction prior to the start of treatment or in the two following readouts. Multivariate analysis revealed that only the TGP score significantly correlated with the PFI (
p
= 0.029247). The TGP is an important prognostic variable for patients with locoregional breast cancer. The presence of CTCs adds no prognostic value to the information already provided by the TGP.</description><identifier>ISSN: 1010-4283</identifier><identifier>EISSN: 1423-0380</identifier><identifier>DOI: 10.1007/s13277-015-3529-5</identifier><identifier>PMID: 25976504</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Adult ; Aged ; Biomarkers ; Biomarkers, Tumor - analysis ; Biomedical and Life Sciences ; Biomedicine ; Breast Neoplasms - classification ; Breast Neoplasms - genetics ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Cancer Research ; Chemotherapy ; Drug therapy ; Female ; Follow-Up Studies ; Gene Expression Profiling ; Humans ; Keratin-19 - genetics ; Leukocytes, Mononuclear - pathology ; Middle Aged ; Neoplasm Staging ; Neoplastic Cells, Circulating - pathology ; Polymerase chain reaction ; Prognosis ; Real-Time Polymerase Chain Reaction ; Receptor, ErbB-2 - genetics ; Research Article ; RNA, Messenger - genetics ; Survival Rate ; Tumors</subject><ispartof>Tumor biology, 2015-09, Vol.36 (10), p.8075-8083</ispartof><rights>International Society of Oncology and BioMarkers (ISOBM) 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-66763e07a891cb01bfd9b1c879b026605eab0b124fd5fcd78826d7e46fd374913</citedby><cites>FETCH-LOGICAL-c475t-66763e07a891cb01bfd9b1c879b026605eab0b124fd5fcd78826d7e46fd374913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13277-015-3529-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13277-015-3529-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25976504$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kuniyoshi, Renata K.</creatorcontrib><creatorcontrib>de Sousa Gehrke, Flávia</creatorcontrib><creatorcontrib>Alves, Beatriz C. A.</creatorcontrib><creatorcontrib>Vilas-Bôas, Viviane</creatorcontrib><creatorcontrib>Coló, Anna E.</creatorcontrib><creatorcontrib>Sousa, Naiara</creatorcontrib><creatorcontrib>Nunes, João</creatorcontrib><creatorcontrib>Fonseca, Fernando L. A.</creatorcontrib><creatorcontrib>Del Giglio, Auro</creatorcontrib><title>Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer</title><title>Tumor biology</title><addtitle>Tumor Biol</addtitle><addtitle>Tumour Biol</addtitle><description>The gene profile of primary tumors, as well as the identification of circulating tumor cells (CTCs), can provide important prognostic and predictive information. In this study, our objective was to perform tumor gene profiling (TGP) in combination with CTC characterization in women with nonmetastatic breast cancer. Biological samples (from peripheral blood and tumors) from 167 patients diagnosed with stage I, II, and III mammary carcinoma, who were also referred for adjuvant/neoadjuvant chemotherapy, were assessed for the following parameters: (a) the presence of CTCs identified by the expression of CK-19 and c-erbB-2 in the peripheral blood mononuclear cell (PBMC) fraction by quantitative reverse transcription PCR (RT-PCR) and (b) the TGP, which was determined by analyzing the expression of 21 genes in paraffin-embedded tissue samples by quantitative multiplex RT-PCR with the Plexor® system. We observed a statistically significant correlation between the progression-free interval (PFI) and the clinical stage (
p
= 0.000701), the TGP score (
p
= 0.006538), and the presence of hormone receptors in the tumor (
p
= 0.0432). We observed no correlation between the PFI and the presence or absence of CK-19 or HER2 expression in the PBMC fraction prior to the start of treatment or in the two following readouts. Multivariate analysis revealed that only the TGP score significantly correlated with the PFI (
p
= 0.029247). The TGP is an important prognostic variable for patients with locoregional breast cancer. The presence of CTCs adds no prognostic value to the information already provided by the TGP.</description><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Breast Neoplasms - classification</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer Research</subject><subject>Chemotherapy</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gene Expression Profiling</subject><subject>Humans</subject><subject>Keratin-19 - genetics</subject><subject>Leukocytes, Mononuclear - pathology</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Neoplastic Cells, Circulating - pathology</subject><subject>Polymerase chain reaction</subject><subject>Prognosis</subject><subject>Real-Time Polymerase Chain Reaction</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Research Article</subject><subject>RNA, Messenger - genetics</subject><subject>Survival Rate</subject><subject>Tumors</subject><issn>1010-4283</issn><issn>1423-0380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkUFvFSEUhYnR2Fr9AW4MiRs3oxdmgGFpGq1NmrjRNQHmzpM6D16BifHfy2SqMSYmXQG53zn3Xg4hLxm8ZQDqXWE9V6oDJrpecN2JR-ScDbzvoB_hcbsDg27gY39GnpVyCw3UWj4lZ1xoJQUM5-TuCiPSU05zWEI8UBsn6kP262Lr9q7rMWXqcVkKtYW6kI42f8dMa9pUh5hKDZ6mmZ6aAGMt9Eeo3-iSfMp4CCnahbqMtlTqbfSYn5Mns10Kvrg_L8jXjx--XH7qbj5fXV--v-n8oETtpFSyR1B21Mw7YG6etGN-VNoBlxIEWgeO8WGexOwnNY5cTgoHOU-9GjTrL8ib3beNebdiqeYYyraIjZjWYpiSo5Aj1-IBKOeaC6l1Q1__g96mNbcldwq0ZmJoFNspn1MpGWdzyqF93E_DwGzRmT060xIxW3RmG-LVvfPqjjj9UfzOqgF8B0orxQPmv1r_1_UXm-ykVQ</recordid><startdate>20150901</startdate><enddate>20150901</enddate><creator>Kuniyoshi, Renata K.</creator><creator>de Sousa Gehrke, Flávia</creator><creator>Alves, Beatriz C. A.</creator><creator>Vilas-Bôas, Viviane</creator><creator>Coló, Anna E.</creator><creator>Sousa, Naiara</creator><creator>Nunes, João</creator><creator>Fonseca, Fernando L. A.</creator><creator>Del Giglio, Auro</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20150901</creationdate><title>Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer</title><author>Kuniyoshi, Renata K. ; de Sousa Gehrke, Flávia ; Alves, Beatriz C. A. ; Vilas-Bôas, Viviane ; Coló, Anna E. ; Sousa, Naiara ; Nunes, João ; Fonseca, Fernando L. A. ; Del Giglio, Auro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-66763e07a891cb01bfd9b1c879b026605eab0b124fd5fcd78826d7e46fd374913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Breast Neoplasms - classification</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer Research</topic><topic>Chemotherapy</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gene Expression Profiling</topic><topic>Humans</topic><topic>Keratin-19 - genetics</topic><topic>Leukocytes, Mononuclear - pathology</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Neoplastic Cells, Circulating - pathology</topic><topic>Polymerase chain reaction</topic><topic>Prognosis</topic><topic>Real-Time Polymerase Chain Reaction</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Research Article</topic><topic>RNA, Messenger - genetics</topic><topic>Survival Rate</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kuniyoshi, Renata K.</creatorcontrib><creatorcontrib>de Sousa Gehrke, Flávia</creatorcontrib><creatorcontrib>Alves, Beatriz C. A.</creatorcontrib><creatorcontrib>Vilas-Bôas, Viviane</creatorcontrib><creatorcontrib>Coló, Anna E.</creatorcontrib><creatorcontrib>Sousa, Naiara</creatorcontrib><creatorcontrib>Nunes, João</creatorcontrib><creatorcontrib>Fonseca, Fernando L. A.</creatorcontrib><creatorcontrib>Del Giglio, Auro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Tumor biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kuniyoshi, Renata K.</au><au>de Sousa Gehrke, Flávia</au><au>Alves, Beatriz C. A.</au><au>Vilas-Bôas, Viviane</au><au>Coló, Anna E.</au><au>Sousa, Naiara</au><au>Nunes, João</au><au>Fonseca, Fernando L. A.</au><au>Del Giglio, Auro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer</atitle><jtitle>Tumor biology</jtitle><stitle>Tumor Biol</stitle><addtitle>Tumour Biol</addtitle><date>2015-09-01</date><risdate>2015</risdate><volume>36</volume><issue>10</issue><spage>8075</spage><epage>8083</epage><pages>8075-8083</pages><issn>1010-4283</issn><eissn>1423-0380</eissn><abstract>The gene profile of primary tumors, as well as the identification of circulating tumor cells (CTCs), can provide important prognostic and predictive information. In this study, our objective was to perform tumor gene profiling (TGP) in combination with CTC characterization in women with nonmetastatic breast cancer. Biological samples (from peripheral blood and tumors) from 167 patients diagnosed with stage I, II, and III mammary carcinoma, who were also referred for adjuvant/neoadjuvant chemotherapy, were assessed for the following parameters: (a) the presence of CTCs identified by the expression of CK-19 and c-erbB-2 in the peripheral blood mononuclear cell (PBMC) fraction by quantitative reverse transcription PCR (RT-PCR) and (b) the TGP, which was determined by analyzing the expression of 21 genes in paraffin-embedded tissue samples by quantitative multiplex RT-PCR with the Plexor® system. We observed a statistically significant correlation between the progression-free interval (PFI) and the clinical stage (
p
= 0.000701), the TGP score (
p
= 0.006538), and the presence of hormone receptors in the tumor (
p
= 0.0432). We observed no correlation between the PFI and the presence or absence of CK-19 or HER2 expression in the PBMC fraction prior to the start of treatment or in the two following readouts. Multivariate analysis revealed that only the TGP score significantly correlated with the PFI (
p
= 0.029247). The TGP is an important prognostic variable for patients with locoregional breast cancer. The presence of CTCs adds no prognostic value to the information already provided by the TGP.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>25976504</pmid><doi>10.1007/s13277-015-3529-5</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1010-4283 |
| ispartof | Tumor biology, 2015-09, Vol.36 (10), p.8075-8083 |
| issn | 1010-4283 1423-0380 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1768568295 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Adult Aged Biomarkers Biomarkers, Tumor - analysis Biomedical and Life Sciences Biomedicine Breast Neoplasms - classification Breast Neoplasms - genetics Breast Neoplasms - mortality Breast Neoplasms - pathology Cancer Research Chemotherapy Drug therapy Female Follow-Up Studies Gene Expression Profiling Humans Keratin-19 - genetics Leukocytes, Mononuclear - pathology Middle Aged Neoplasm Staging Neoplastic Cells, Circulating - pathology Polymerase chain reaction Prognosis Real-Time Polymerase Chain Reaction Receptor, ErbB-2 - genetics Research Article RNA, Messenger - genetics Survival Rate Tumors |
| title | Gene profiling and circulating tumor cells as biomarker to prognostic of patients with locoregional breast cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T20%3A06%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gene%20profiling%20and%20circulating%20tumor%20cells%20as%20biomarker%20to%20prognostic%20of%20patients%20with%20locoregional%20breast%20cancer&rft.jtitle=Tumor%20biology&rft.au=Kuniyoshi,%20Renata%20K.&rft.date=2015-09-01&rft.volume=36&rft.issue=10&rft.spage=8075&rft.epage=8083&rft.pages=8075-8083&rft.issn=1010-4283&rft.eissn=1423-0380&rft_id=info:doi/10.1007/s13277-015-3529-5&rft_dat=%3Cproquest_cross%3E3836286231%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1722099154&rft_id=info:pmid/25976504&rfr_iscdi=true |